| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/05/2011 | DE102009051799A1 Bifunktionale Prodrugs und Drugs Bifunctional prodrugs and Drugs |
| 05/05/2011 | CA2779512A1 Vault complexes for cytokine delivery |
| 05/05/2011 | CA2779496A1 Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use |
| 05/05/2011 | CA2779316A1 Paclitaxel/steroidal compound |
| 05/05/2011 | CA2779166A1 Submicro emulsion of paclitaxel using steroid complex as intermediate carrier |
| 05/05/2011 | CA2779009A1 Novel antitumoral use of cabazitaxel |
| 05/05/2011 | CA2778990A1 Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same |
| 05/05/2011 | CA2778680A1 N-containing heteroaryl derivatives as jak3 kinase inhibitors |
| 05/05/2011 | CA2778265A1 Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition |
| 05/05/2011 | CA2777896A1 Androgen receptor modulating compounds |
| 05/05/2011 | CA2777539A1 Novel therapeutic rna interference technology targeted to the pdx-1 oncogene in pdx-1 expressing neuroendocrine tumors |
| 05/05/2011 | CA2777128A1 Methods and compositions for treating cancer |
| 05/05/2011 | CA2776925A1 Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt |
| 05/05/2011 | CA2776319A1 Ite for cancer intervention and eradication |
| 05/04/2011 | EP2316976A1 Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| 05/04/2011 | EP2316951A1 Binding domain-immunoglobulin fusion proteins |
| 05/04/2011 | EP2316944A2 Binding agents: chimeric ligand/receptor proteins |
| 05/04/2011 | EP2316937A1 Dna encoding polypeptide involved in biosynthesis of herboxidiene |
| 05/04/2011 | EP2316935A1 Aptamer against il-17 and use thereof |
| 05/04/2011 | EP2316924A2 Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals |
| 05/04/2011 | EP2316923A2 Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals |
| 05/04/2011 | EP2316922A1 Neutralizing human anti-IGFR antibody |
| 05/04/2011 | EP2316921A1 Neutralizing human anti-IGFR antibody |
| 05/04/2011 | EP2316857A1 Monoclonal antibodies that specifically bind to folate receptor alpha |
| 05/04/2011 | EP2316855A1 Antihuman Alpha-9 integrin antibody and use of the same |
| 05/04/2011 | EP2316852A1 Stabilized single domain antibodies |
| 05/04/2011 | EP2316851A1 Antibody inhibitors of GDF-8 and uses thereof |
| 05/04/2011 | EP2316845A1 Specific binding agents of human angiopoietin-2 |
| 05/04/2011 | EP2316843A1 Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma |
| 05/04/2011 | EP2316835A1 Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases |
| 05/04/2011 | EP2316831A1 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer |
| 05/04/2011 | EP2316491A1 Cell proliferation inhibitor |
| 05/04/2011 | EP2316488A1 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
| 05/04/2011 | EP2316487A1 Recombinant IL-9 antibodies & uses thereof |
| 05/04/2011 | EP2316486A2 Cripto blocking antibodies and uses thereof |
| 05/04/2011 | EP2316484A1 Antibody specifically binding to C-MET and use thereof |
| 05/04/2011 | EP2316478A1 Targeted therapeutic vaccine against P-glycoprotein 170 for inhibiting multi-drug resistance in the treatment of cancers |
| 05/04/2011 | EP2316477A1 Immunogenic LHRH compositions and methods relating thereto |
| 05/04/2011 | EP2316476A2 Antigenic peptides derived from telomerase |
| 05/04/2011 | EP2316471A1 Pharmaceutical formulations for sustained drug delivery |
| 05/04/2011 | EP2316467A1 Use of a prolactin variant for treating cancer |
| 05/04/2011 | EP2316466A2 Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation |
| 05/04/2011 | EP2316459A1 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
| 05/04/2011 | EP2316455A1 Pharmaceutical compositions for treating cancer |
| 05/04/2011 | EP2316452A1 Pyrrol derivatives, uses thereof |
| 05/04/2011 | EP2316450A1 Amino-methyl substituted tetracycline compounds |
| 05/04/2011 | EP2316377A1 Drug-Delivery Endovascular Stent And Method For Treating Restenosis |
| 05/04/2011 | EP2315781A2 Fgf-r4 receptor-specific antagonists |
| 05/04/2011 | EP2315771A2 Glycopeptide constructs and uses thereof |
| 05/04/2011 | EP2315767A2 Pyridino-pyridinone derivatives, preparation thereof, and therapeutic use thereof |
| 05/04/2011 | EP2315764A2 Crystalline form of sunitinib and processes for its preparation |
| 05/04/2011 | EP2315761A1 Pharmaceutical compounds |
| 05/04/2011 | EP2315756A2 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
| 05/04/2011 | EP2315754A1 Pyrimidyl sulfonaminde derivative and its use for the treatment of chemokine mediated diseases |
| 05/04/2011 | EP2315749A2 New therapeutic agents |
| 05/04/2011 | EP2315745A2 2-methylene-19, 26-dinor-(20s, 22e, 25r)-vitamin d analogs |
| 05/04/2011 | EP2315744A2 2-methylene-20(21)-dehydro-19-nor-vitamin d analogs |
| 05/04/2011 | EP2315604A2 Dicarba-analgues of octreotide |
| 05/04/2011 | EP2315601A1 Combination of a c-met antagonist and an aminoheteroaryl compound for the treatment of cancer |
| 05/04/2011 | EP2315599A1 Pharmaceutical compositions comprising antibodies binding to ebv (epstein-barr virus) protein barf1 |
| 05/04/2011 | EP2315596A1 Process for extraction of glucosinolate s from broccoli seeds |
| 05/04/2011 | EP2315594A1 Methods of treating a meiotic kinesin-associated disease |
| 05/04/2011 | EP2128248B1 Oligonucleotide compositions with enhanced efficiency |
| 05/04/2011 | EP2123288B1 C70 fullerene-containing liposome, method for producing the same, and use of the same |
| 05/04/2011 | EP2048145B9 Protein kinase c activity enhancer containing alkyl ether derivative or salt thereof |
| 05/04/2011 | EP2044036B1 [4,5']bipyrimidinyl-6,4'-diamine derivatives as protein kinase inhbitors |
| 05/04/2011 | EP1951716B1 Aminopyrimidines useful as kinase inhibitors |
| 05/04/2011 | EP1667726B1 Polyacetal drug conjugates as release system |
| 05/04/2011 | EP1551412B1 Pharmaceutical compositions for the treatment of diseases related to neurotrophines |
| 05/04/2011 | EP1465666B1 Multicomponent assemblies having enhanced binding properties for diagnosis and therapy |
| 05/04/2011 | EP1414439B1 Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine |
| 05/04/2011 | EP1414299B1 Method for making a homogenous doxorubicin -transferrin conjugate |
| 05/04/2011 | EP1383532B1 Combination therapy |
| 05/04/2011 | EP1317448B2 Pyrazole compounds useful as protein kinase inhibitors |
| 05/04/2011 | CN1980672B Carboline derivatives useful in the inhibition of angiogenesis |
| 05/04/2011 | CN1923232B Medicine composition for dispersing pathogenic wind and extinguishing phlegm, absorbing clots and softening hard masses, preparation method and use thereof |
| 05/04/2011 | CN1847229B 2,4,8- trisubstituted-8H- pyridine[2,3-d] pyridine -7-one compound |
| 05/04/2011 | CN1748704B Aqueous preparation for injection and its stabilizing method |
| 05/04/2011 | CN102046780A Method for production of transfected cell |
| 05/04/2011 | CN102046660A Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof |
| 05/04/2011 | CN102046657A Antibodies directed to angiopoietin-1 and angiopoietin-2 and use thereof |
| 05/04/2011 | CN102046632A Azo and diaza derivatives and uses thereof in phototherapy |
| 05/04/2011 | CN102046628A Alpha helix mimetics and methods relating thereto |
| 05/04/2011 | CN102046617A Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-n-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2ylamino)-phenyl]-benzamide |
| 05/04/2011 | CN102046605A Dihydropyrazole derivatives as tyrosine kinase modulators for the treatment of tumors |
| 05/04/2011 | CN102046200A Therapeutic for hepatic cancer |
| 05/04/2011 | CN102046199A Methods of treatment using anti-mif antibodies |
| 05/04/2011 | CN102046187A Method and compositions for treatment of cancer |
| 05/04/2011 | CN102046180A Compositions and methods for immunotherapy |
| 05/04/2011 | CN102041316A Application of micro ribonucleic acid (miRNA)-219 compound as marker of brain glioma |
| 05/04/2011 | CN102041270A Construction and screening of siRNAs (small interfering RANs) expression vectors of targeted DEC1 (differentiated embryo-chondrocyte expressed gene 1) resulting in gastric cancer and application thereof |
| 05/04/2011 | CN102041259A GPR116 (G-protein coupled Receptor) gene, receptor protein coded by same and application of the GPR116 gene |
| 05/04/2011 | CN102041256A Human miR-486-5p antisense nucleic acid and application thereof |
| 05/04/2011 | CN102041175A Method for extracting total volatile oil and total alkaloids from zanthoxylum echinocarpum |
| 05/04/2011 | CN102040749A Ganoderma sinense mycelium polysaccharide refined substance as well as preparation method and use thereof |
| 05/04/2011 | CN102040748A Ganoderma sinensis mycelium anti-tumor polysaccharide component GS-C as well as preparation method and application thereof |
| 05/04/2011 | CN102040667A Method for biologically removing protein from sea cucumber polysaccharide |
| 05/04/2011 | CN102040662A Antibodies against human IL-21 receptor and uses therefor |
| 05/04/2011 | CN102040643A Ciclesonide nitrate derivative |
| 05/04/2011 | CN102040627A Phosphorus-containing compound and its medicament application for treatment of bone metabolism abnormity |